Related Experiment Video

Updated: Jun 19, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme

D E Newby1, T McDonagh, P F Currie

  • 1Department of Cardiology, Royal Infirmary, Edinburgh, Scotland, UK.

European Heart Journal
|January 14, 1999
PubMed

Insights

Candoxatril improved exercise capacity in patients with chronic heart failure on angiotensin converting enzyme inhibitor therapy. This neutral endopeptidase inhibitor showed benefits in exercise time but not in overall clinical status or quality of life.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) is a significant cardiovascular condition.
  • Angiotensin converting enzyme (ACE) inhibitors are standard therapy for CHF.
  • Novel therapeutic targets are needed to further improve outcomes in CHF patients.

Purpose of the Study:

  • To evaluate the efficacy of candoxatril, a neutral endopeptidase (NEP) inhibitor, in patients with mild to moderate CHF.
  • To assess the impact of candoxatril on exercise capacity, clinical status, and quality of life.
  • To determine if candoxatril offers benefits when added to existing ACE inhibitor therapy.

Main Methods:

  • A double-blind, randomized, placebo-controlled trial was conducted.
  • 110 patients with mild to moderate CHF receiving ACE inhibitors were enrolled.
  • Patients received either candoxatril (100 mg twice daily) or placebo for 84 days, with exercise tests performed regularly.

Main Results:

  • Candoxatril significantly increased total exercise time by 34.1 seconds compared to placebo (P=0.02).
  • No significant improvements were observed in functional class, clinical status, or quality of life scores.
  • A trend towards a small reduction in blood pressure was noted in the candoxatril group.

Conclusions:

  • Candoxatril enhances exercise capacity in patients with chronic heart failure on ACE inhibitor therapy.
  • While improving exercise tolerance, candoxatril did not significantly alter broader clinical outcomes or quality of life in this cohort.
Abstract

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.